Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Tax Provisions (2019 - 2023)

Historic Tax Provisions for Lineage Cell Therapeutics (LCTX) over the last 5 years, with Q1 2023 value amounting to -$1.8 million.

  • Lineage Cell Therapeutics' Tax Provisions changed N/A to -$1.8 million in Q1 2023 from the same period last year, while for Dec 2023 it was -$1.8 million, marking a year-over-year increase of 8754.66%. This contributed to the annual value of -$1.8 million for FY2023, which is 43327.17% down from last year.
  • As of Q1 2023, Lineage Cell Therapeutics' Tax Provisions stood at -$1.8 million.
  • Lineage Cell Therapeutics' Tax Provisions' 5-year high stood at $4.4 million during Q1 2019, with a 5-year trough of -$14.0 million in Q4 2019.
  • Its 4-year average for Tax Provisions is -$1.4 million, with a median of $541000.0 in 2022.
  • Over the last 5 years, Lineage Cell Therapeutics' Tax Provisions had its largest YoY gain of 15345.85% in 2022, and its largest YoY loss of 15345.85% in 2022.
  • Lineage Cell Therapeutics' Tax Provisions (Quarter) stood at -$14.0 million in 2019, then surged by 92.78% to -$1.0 million in 2021, then soared by 153.46% to $541000.0 in 2022, then tumbled by 433.27% to -$1.8 million in 2023.
  • Its last three reported values are -$1.8 million in Q1 2023, $541000.0 for Q3 2022, and -$1.0 million during Q3 2021.